【药明生物(02269.HK)2026中期业绩强劲：收益118亿元，经调整归母净利同比增长38.4%】智通财经APP讯，药明生物(02269.HK)2026年中报显示，公司上半年业绩亮眼，收入快速攀升，利润强劲增长。收益118亿元，同比增长18.4%(按美元计同比增长23.4%);经调整毛利57亿元，经调整毛利率48.4%，同比提升280个基点;经调整归母净利33亿元，同比增长38.4%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.